相關商品
商品簡介
作者簡介
名人/編輯推薦
目次
商品簡介
《癌癥研究及其治療的最新進展》集全球癌癥研究與治療領域的高水平專家集體之力，全面介紹了目前癌癥領域的最新研究進展。內容包括：生物治療的研究和應用的詳細描述，超級干擾素的抗癌作用；抗體治療、免疫治療、腫瘤干細胞研究，化學治療的研究和應用的介紹；細胞治療（特異性及非特異性）；中藥臨床和三氧化砷治療白血病；對全球發病率最高的肺癌、腸癌的研究，針對中國癌癥發病率特別高的食道癌、鼻咽癌的研究等。
《癌癥研究及其治療的最新進展》的讀者對象為所有從事癌癥研究與治療的專家、研究生、大學生。
作者簡介
作者:(美)帕斯卡、時玉舫
名人/編輯推薦
帕斯卡、時玉舫編著的這本《癌癥研究及其治療的最新進展》以全英文的方式，以21章篇幅，分別介紹了癌癥生物治療的研究和應用；超級干擾素的抗癌作用；抗體治療、免疫治療、腫瘤干細胞研究；化學治療的研究和應用的介紹；細胞治療（特異性及非特異性）；中藥臨床和三氧化砷治療白血病；對全球發病率最高的肺癌、腸癌的研究，針對中國癌癥發病率特別高的食道癌、鼻咽癌的研究等內容。
目次
Preface
List of Contributors
1 Cancer Biotherapy: Progress in China
2 Cancer Targeting Gene-Viro-Therapy and Its Promising Future
3 Relationship Between Antiproliferative Activities and Class I MHC Surface Expression of Mouse Interferon Proteins on B16-Fl0 Melanoma Cells
4 Mitotic Regulator Hecl as a Potential Target for Cancer Therapy
5 Advances in Liposome-Based Targeted Gene Therapy of Cancer
6 Rewiring the Intracellular Signaling Network in Cancer
7 Research and Development of Highly Potent Antibody-Based Drug Conjugates and Fusion Proteins for Cancer Therapy
8 Cancer Stem Cell
9 p53: A Target and a Biomarker of Cancer Therapy?
10 Recombinant Adenoviral-p53 Agent （Gendicine）: Quality Control, Mecharusm of Action, and Its Use for Treatment of Malignant Tumors
11 Three-Dimensional Tumor Model and T-Lymphocytes Immunotherapy for Cancer
12 Advances in Cancer Chemotherapeutic Drug Research in China
13 Doxorubicin Cardiotoxicity Revisited: ROS Versus Top2
14 Biochemistry and Pharmacology of Human ABCC1/MRP1 and Its Role in Detoxification and in Multidrug Resistance of Cancer Chemotherapy
15 The Role of Traditional Chinese Medicine in Clinical Oncology
16 Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia and Glioma: Experimental Studies, Clinical Applications, and Perspectives
17 Recent Advances in Nasopharyngeal Carcinoma Research and Its Pathogenesis
18 EsophageaI Carcinoma
19 Research on Colorectal Cancer in China
20 Molecular and Cellular Characteristics of Small CeH Lung Cancer: Implications for Molecular-Targeted Cancer Therapy
21 Possibility to Partly Win the War Against Cancer
About the Editors
List of Contributors
1 Cancer Biotherapy: Progress in China
2 Cancer Targeting Gene-Viro-Therapy and Its Promising Future
3 Relationship Between Antiproliferative Activities and Class I MHC Surface Expression of Mouse Interferon Proteins on B16-Fl0 Melanoma Cells
4 Mitotic Regulator Hecl as a Potential Target for Cancer Therapy
5 Advances in Liposome-Based Targeted Gene Therapy of Cancer
6 Rewiring the Intracellular Signaling Network in Cancer
7 Research and Development of Highly Potent Antibody-Based Drug Conjugates and Fusion Proteins for Cancer Therapy
8 Cancer Stem Cell
9 p53: A Target and a Biomarker of Cancer Therapy?
10 Recombinant Adenoviral-p53 Agent （Gendicine）: Quality Control, Mecharusm of Action, and Its Use for Treatment of Malignant Tumors
11 Three-Dimensional Tumor Model and T-Lymphocytes Immunotherapy for Cancer
12 Advances in Cancer Chemotherapeutic Drug Research in China
13 Doxorubicin Cardiotoxicity Revisited: ROS Versus Top2
14 Biochemistry and Pharmacology of Human ABCC1/MRP1 and Its Role in Detoxification and in Multidrug Resistance of Cancer Chemotherapy
15 The Role of Traditional Chinese Medicine in Clinical Oncology
16 Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia and Glioma: Experimental Studies, Clinical Applications, and Perspectives
17 Recent Advances in Nasopharyngeal Carcinoma Research and Its Pathogenesis
18 EsophageaI Carcinoma
19 Research on Colorectal Cancer in China
20 Molecular and Cellular Characteristics of Small CeH Lung Cancer: Implications for Molecular-Targeted Cancer Therapy
21 Possibility to Partly Win the War Against Cancer
About the Editors
您曾經瀏覽過的商品
購物須知
大陸出版品因裝訂品質及貨運條件與台灣出版品落差甚大，除封面破損、內頁脫落等較嚴重的狀態，其餘商品將正常出貨。
特別提醒：部分書籍附贈之內容(如音頻mp3或影片dvd等)已無實體光碟提供，需以QR CODE 連結至當地網站註冊“並通過驗證程序”，方可下載使用。
無現貨庫存之簡體書，將向海外調貨：
海外有庫存之書籍，等候約45個工作天;
海外無庫存之書籍，平均作業時間約60個工作天，然不保證確定可調到貨，尚請見諒。
為了保護您的權益，「三民網路書店」提供會員七日商品鑑賞期(收到商品為起始日)。
若要辦理退貨，請在商品鑑賞期內寄回，且商品必須是全新狀態與完整包裝(商品、附件、發票、隨貨贈品等)否則恕不接受退貨。
優惠價：87
1034
海外經銷商無庫存，到貨日平均30天至45天